Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Products under Development by Stage of Development | 7 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Products under Development by Therapy Area | 8 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Products under Development by Indication | 9 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Products under Development by Companies | 12 | 2 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Products under Development by Universities/Institutes | 14 | 2 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Companies Involved in Therapeutics Development | 21 | 4 |
| Astex Pharmaceuticals, Inc. | 21 | 1 |
| Presage Biosciences, Inc. | 22 | 1 |
| Tiziana Life Sciences Plc | 23 | 1 |
| Tragara Pharmaceuticals, Inc. | 24 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Drug Profiles | 25 | 11 |
| AT-7519 Drug Profile | 25 | 3 |
| milciclib Drug Profile | 28 | 2 |
| Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease Drug Profile | 30 | 1 |
| TG-02 Drug Profile | 31 | 3 |
| voruciclib Drug Profile | 34 | 2 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Dormant Projects | 36 | 2 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Discontinued Products | 38 | 1 |
| Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Featured News &Press Releases | 39 | 11 |
| Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors | 39 | 1 |
| Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer | 39 | 1 |
| Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 | 40 | 1 |
| May 28, 2014: Tragara's TG02 is Highly Active in CLL Cells Derived from Patients who have Failed Treatment with Ibrutinib | 41 | 1 |
| May 14, 2014: Phase II data of Nerviano Medical Science s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO | 42 | 1 |
| Apr 07, 2014: New Preclinical Data of Tragara s TG02 in Acute Leukemia at AACR Meeting in San Diego | 42 | 1 |
| Dec 06, 2013: New Preclinical Data of Tragara s TG02 in Multiple Myeloma and Leukemia to be Presented at ASH 2013 Annual Meeting | 43 | 1 |
| Dec 03, 2013: Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma | 43 | 1 |
| Sep 12, 2013: Tragara Announces Oral Presentation at Society of Hematology Oncology Annual Meeting | 44 | 1 |
| May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02 | 44 | 1 |
| May 22, 2012: Piramal Healthcare To Present Phase I Data For New Oral Anticancer Molecule At ASCO Annual Meeting | 45 | 2 |
| Apr 03, 2012: Piramal Healthcare To Present Preclinical Data On Tumor Drug P1446A-05 At 2012 AACR Annual Meeting | 47 | 1 |
| Apr 02, 2012: Tragara Pharma Announces Presentation Of Preclinical Data Of TG02 At 2012 AACR Annual Meeting | 47 | 1 |
| Sep 14, 2011: Tragara And Multiple Myeloma Research Foundation Initiate Phase I Clinical Study Of TG02 In Multiple Myeloma Patients | 48 | 1 |
| Mar 23, 2011: Tragara To Present TG02 Poster At 102nd AACR Annual Meeting | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |